GSK plc (GSK.L)
| Previous Close | 1,783.50 |
| Open | 1,773.50 |
| Bid | 1,700.00 x 0 |
| Ask | 1,800.00 x 0 |
| Day's Range | 1,764.50 - 1,779.50 |
| 52 Week Range | 1,302.60 - 1,823.50 |
| Volume | |
| Avg. Volume | 7,762,452 |
| Market Cap | 73.573B |
| Beta (5Y Monthly) | 0.27 |
| PE Ratio (TTM) | 16.28 |
| EPS (TTM) | 1.09 |
| Earnings Date | Jul 31, 2024 |
| Forward Dividend & Yield | 0.60 (3.36%) |
| Ex-Dividend Date | May 16, 2024 |
| 1y Target Est | N/A |
Evening StandardFTSE 100 Live 17 May: LandSec shares fall on results, GSK in £1.25bn final Haleon stake sale
GSK and Land Securities are in the FTSE 100 spotlight after the drugs giant sold its final Haleon shares and the property firm posted results. The sale of GSK’s remaining 4% stake raised £1.25 billion, having held 13% following its 2022 demerger of the Panadol and Sensodyne business. Land Securities revealed a smaller full-year loss of £341 million amid “robust” rental growth across its estate.
Yahoo Finance UKTrending tickers: Tesla, Reddit, Walmart and GSK
The latest investor updates on stocks that are trending on Friday.
BloombergGSK to Sell Remaining $1.6 Billion Stake in Haleon
(Bloomberg) -- GSK Plc will sell its remaining stake in Haleon Plc for £1.25 billion ($1.6 billion), completing the drugmaker’s separation from the consumer health company.Most Read from BloombergChina Attempts to End Property Crisis With Broad Rescue PackageWith a BlackRock CEO, $9 Trillion Vanguard Braces for TurbulenceUS Inflation Data Was Accidentally Released 30 Minutes EarlyPutin and Xi Vow to Step Up Fight to Counter US ‘Containment’Jamie Dimon Sees ‘Lot of Inflationary Forces in Front of
